PTH administration increases bone mass in rodents and in humans. PTH-related
protein (
PTHrP) binds to and signals via the skeletal PTH receptor. Administration of
PTHrP on a once daily basis increases bone mineral content in rats. In humans, PTHrP-(1-36) is equipotent to PTH-(1-34) and is active when administered s.c. These findings suggest that
PTHrP might have therapeutic benefit in the treatment of
osteoporosis. In this study, 13 postmenopausal
estrogen-deficient women received a single daily s.c. dose of PTHrP-(1-36) for a 14-day period to determine whether PTHrP-(1-36) 1) could be given in doses that do not alter systemic
mineral homeostasis, but increase markers of bone turnover; and 2) is tolerated without adverse effects. Daily s.c.
PTHrP-(1-36) administration caused no significant changes in serum
calcium or
phosphorus concentrations, fractional
calcium excretion, the tubular maximum for
phosphorus, fractional
calcium excretion, or plasma 1,25-dihydroxyvitamin D concentrations. Nephrogenous cAMP and endogenous
PTH-(1-84) declined. Importantly, markers of bone formation trended upward, as reported in subjects treated with PTH. In marked contrast to findings in PTH-treated subjects, in
PTHrP-treated subjects, markers of
bone resorption declined in a highly significant fashion. These observations indicate that
PTHrP-(1-36) treatment uncouples bone formation from resorption, in favor of formation. This uncoupling, if it were to continue over the longer term, would predict that
PTHrP-(1-36) might be a potent anabolic therapeutic agent for
osteoporosis.